Sonya Bhatia

Sonya Bhatia, PhD, is a Director of Life Science Investments, CNS at Bayshore where she focuses on biotechnology and healthcare investments in Central Nervous System (CNS) disorders including Parkinson’s disease, Autism Spectrum Disorders (ASD) and Bipolar Disease. Her work spans therapeutics, diagnostics, and digital health, with a focus on advancing treatments and improving patient care.

Before joining Bayshore, Sonya was Vice President on the Goldman Sachs Life Sciences Investing team, where she helped build the platform and supported investments across oncology, immunology and rare disease. She began her career on the Biotechnology Equity Research team at Goldman Sachs.

Sonya holds a PhD in Genetics from Harvard University and a BA in Neuroscience from Smith College.